fda stops semaglutide compounding 📢 has determined the shortage of injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. Patients and prescribers may still see intermittent and limited localized supply disruptions as the FDA moves to limit compounding

Digital delivery leads because aftercare requires frequent check-ins and behavior support

While preclinical and clinical data provide insights, much of the evidence remains preliminary, with ongoing needs for long-term studies

Genomic Research Campbell et al

Smart Battery Technology When connected to a Spektrum Smart charger, unique parameters and health of your Smart LiPo battery upload from the Smart memory microchip integrated into the battery

Discussion In this study, we show that replacement of the murine GLP-1R with human GLP-1R results in a similar metabolic phenotype

Practice Guidance from the AASLD;Hepatology 2018;67:328-357 Likelihood of NASH and fibrosis in patients with NAFLD Patients at risk for clinical progression Steatosis = 1 Ballooning = 1 Inflammation = 1 NAS (NAFLD Activity Score) = 4 = F2 Adapted from Konerman MA